CA2589989A1 - The use of the neurotoxic component of a botulinum toxin for the treatment of exessive sweating - Google Patents

The use of the neurotoxic component of a botulinum toxin for the treatment of exessive sweating

Info

Publication number
CA2589989A1
CA2589989A1 CA002589989A CA2589989A CA2589989A1 CA 2589989 A1 CA2589989 A1 CA 2589989A1 CA 002589989 A CA002589989 A CA 002589989A CA 2589989 A CA2589989 A CA 2589989A CA 2589989 A1 CA2589989 A1 CA 2589989A1
Authority
CA
Canada
Prior art keywords
botulinum toxin
sweating
exessive
treatment
neurotoxic component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002589989A
Other languages
French (fr)
Other versions
CA2589989C (en
Inventor
Michael W. Grayston
Judith M. Leon
Steven R. Carlson
K. Roger Aoki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan, Inc.
Michael W. Grayston
Judith M. Leon
Steven R. Carlson
K. Roger Aoki
Allergan
Allergan Sales, Inc.
Allergan Sales, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc., Michael W. Grayston, Judith M. Leon, Steven R. Carlson, K. Roger Aoki, Allergan, Allergan Sales, Inc., Allergan Sales, Llc filed Critical Allergan, Inc.
Priority claimed from CA002300766A external-priority patent/CA2300766C/en
Publication of CA2589989A1 publication Critical patent/CA2589989A1/en
Application granted granted Critical
Publication of CA2589989C publication Critical patent/CA2589989C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a method for relieving pain, associated with muscle contractions, a composition and a method of treating conditions such as cholinergic controlled secretions including excessive sweating, lacrimation and mucus secretions and a method for treating smooth muscle disorders including, but not limited to, spasms in the sphincter of the cardiovascular arteriole, gastrointestinal system, urinary, gall bladder and rectum, which method comprises administering to the patient suffering from said disorder or condition a therapeutically effective amount of Botulinum toxin selected from a group consisting of Botulinum toxin types B, C, D, E, F and G.
CA002589989A 1993-12-28 1994-12-16 The use of the neurotoxic component of a botulinum toxin for the treatment of exessive sweating Expired - Lifetime CA2589989C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17399693A 1993-12-28 1993-12-28
US08/173,996 1993-12-28
CA002300766A CA2300766C (en) 1993-12-28 1994-12-16 Neurotoxic component of botulinum toxin for treating cervical dystonia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002300766A Division CA2300766C (en) 1993-12-28 1994-12-16 Neurotoxic component of botulinum toxin for treating cervical dystonia

Publications (2)

Publication Number Publication Date
CA2589989A1 true CA2589989A1 (en) 1995-07-06
CA2589989C CA2589989C (en) 2009-05-12

Family

ID=38236376

Family Applications (6)

Application Number Title Priority Date Filing Date
CA002589968A Abandoned CA2589968A1 (en) 1993-12-28 1994-12-16 The use of the neurotoxic component of a botulinum toxin for the treatment of pain associated with muscle activity or contracture
CA002590540A Expired - Lifetime CA2590540C (en) 1993-12-28 1994-12-16 The use of neurotoxic component of a botulinum toxin for the treatment of excessive mucus secretion
CA002590537A Expired - Lifetime CA2590537C (en) 1993-12-28 1994-12-16 The use of the neurotoxin component of a botulinum toxin for the treatment of excessive lacrimation
CA002589987A Expired - Fee Related CA2589987C (en) 1993-12-28 1994-12-16 Method for treating a cholinergic influenced secretion
CA002590293A Expired - Lifetime CA2590293C (en) 1993-12-28 1994-12-16 Use of the neurotoxic component of botulinum to treat a spastic muscle
CA002589989A Expired - Lifetime CA2589989C (en) 1993-12-28 1994-12-16 The use of the neurotoxic component of a botulinum toxin for the treatment of exessive sweating

Family Applications Before (5)

Application Number Title Priority Date Filing Date
CA002589968A Abandoned CA2589968A1 (en) 1993-12-28 1994-12-16 The use of the neurotoxic component of a botulinum toxin for the treatment of pain associated with muscle activity or contracture
CA002590540A Expired - Lifetime CA2590540C (en) 1993-12-28 1994-12-16 The use of neurotoxic component of a botulinum toxin for the treatment of excessive mucus secretion
CA002590537A Expired - Lifetime CA2590537C (en) 1993-12-28 1994-12-16 The use of the neurotoxin component of a botulinum toxin for the treatment of excessive lacrimation
CA002589987A Expired - Fee Related CA2589987C (en) 1993-12-28 1994-12-16 Method for treating a cholinergic influenced secretion
CA002590293A Expired - Lifetime CA2590293C (en) 1993-12-28 1994-12-16 Use of the neurotoxic component of botulinum to treat a spastic muscle

Country Status (1)

Country Link
CA (6) CA2589968A1 (en)

Also Published As

Publication number Publication date
CA2589987A1 (en) 1995-07-06
CA2589968A1 (en) 1995-07-06
CA2589987C (en) 2008-05-20
CA2590537C (en) 2009-10-13
CA2590540A1 (en) 1995-07-06
CA2589989C (en) 2009-05-12
CA2590293A1 (en) 1995-07-06
CA2590537A1 (en) 1995-07-06
CA2590293C (en) 2009-05-12
CA2590540C (en) 2009-05-05

Similar Documents

Publication Publication Date Title
CA2180011A1 (en) Botulinum toxins for treating sweating
WO1995017904B1 (en) Botulinum toxins for treating various disorders and associated pain
CA2164866A1 (en) Treatment of neuromuscular disorders and conditions with different botulinum serotype
EP2145629A3 (en) Use of neurotoxin therapy for treatment of urologic and related disorders
JP2004518632A5 (en)
CA2164626A1 (en) Multiple botulinum toxins for treating neuromuscular disorders and conditions
CA2245661A1 (en) Multiple sclerosis treatment
CA2071215A1 (en) Method and composition for treating inflammatory bowel disorders
CA2061665A1 (en) Treatment of lower urinary tract disorders
CA2275167A1 (en) The topical use of kappa opioid agonists to treat ocular pain
WO2002039999B1 (en) Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition
CA2136953A1 (en) A method for using lipoprotein associated coagulation inhibitor to treat sepsis
CA2589989A1 (en) The use of the neurotoxic component of a botulinum toxin for the treatment of exessive sweating
CA2300703A1 (en) Method for treating excessive sweating
张安莉 et al. Clinical effect of acupuncture in the treatment of gastrokinetic disturbance
WO1998001125A3 (en) Dextrorotatory isomers of oxybutynin and desethyloxybutynin in the treatment of gastrointestinal hyperactivity
CA2149766A1 (en) Rectal flunisolide compositions for treating inflammatory intestinal disorders
EP0182569A3 (en) Use of 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyridoû1,2-a¨pyrimidine-3-carboxamide for the prevention and treatment of gastrointestinal damages
WO1996029076A3 (en) Treatment of inflammatory bowel disorders with cotinine
Chen Treatment of apoplectic hemiplegia by digital acupoint pressure--a report of 42 cases
夏晓菊 OBSERVATION ON THE THERAPEUTIC EFFECTS OF 282 CASES WITH PAIN TREATED BY ACUPUNCTURE AT XI POINTS
WO1999065511A3 (en) Composition and method for treatment of pseudomonas infection
RU93037466A (en) METHOD FOR TREATING PERIPHERAL NEUROPATHIES
CA2287903A1 (en) Method for treating medical conditions using a microprocessor-based video game
RU99111088A (en) METHOD FOR TREATING STREPTOCOCCUS PNEUMONIAE INFECTION

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20141216